Erman Akkus: HER2 and mCRC on Journal of Clinical Oncology

Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X/Twitter:

“HER2 and mCRC on Journal of Clinical Oncology:

• HER2 gene expression is predictive and prognostic
• High expression -> better survivals
• Low expression -> favors bevacizumab (vs cetuximab)

HER2 amplification is not predictive or prognostic.

• 925 patients, samples from CALGB)/SWOG 80405 trial
• first line
• High HER2 expression: longer PFS (11.6 v 10 months, P = .012) and OS (32 v 25.3 months, P = .033), independent of treatment
• Low expression group, cetuximab ->. worse PFS (HR, 1.38 [1.12 to 1.71]; P = .0027) and OS (HR, 1.28 1.02 to 1.59]; P = .03) compared with bevacizumab.”

Visit the article website.
Source: Erman Akkus/X